Page 137 - 《中国药房》2021年12期

treatment：from bench to bedside[J]. Cancers（Basel）， gression and clinical management of limited progres-
2019，11（9）：1342. sion[J]. Eur J Cancer，2015，51（11）：1435-1443.
[11] PROIETTI I，SKROZA N，BERNARDINI N，et al. Me- [23] BLANC U，LARKIN K J，ARANCE A M，et al. Open-la-
chanisms of acquired BRAF inhibitor resistance in mela- bel，multicentre safety study of vemurafenib in 3 219 pa-
noma：a systematic review[J]. Cancers（Basel），2020，12 tients with BRAF V600 mutation-positive metastatic mela-
（10）：2801. noma：2-year follow-up data and long-term responders’
[12] MANFRED K，JULIO V. Modelling of protein kinase sig- analysis[J]. Eur J Cancer，2017，79：176-184.
naling pathways in melanoma and other cancers[J]. Can- [24] MAIO M，LEWIS K，DEMIDOV L，et al. Adjuvant vemu-
cers，2019，11（4）：1-18. rafenib in resected，BRAFV 600 mutation-positive mela-
[13] INAMDAR G S ，MADHUNAPANTULA S V ， noma（BRIM8）：a randomised，double-blind，placebo-con-
ROBERTSON G P. Targeting the MAPK pathway in mela- trolled，multicentre，phase 3 trial[J]. Lancet Oncol，2018，
noma：why some approaches succeed and other fail[J]. 19（4）：510-520.
Biochem Pharmacol，2010，80（5）：624-637. [25] HALLMEYER S，GONZALEZ R，LAWSON D H，et al.
[14] DANIELLE K D，GENEVIEVE M B. Melanoma：ad- Vemurafenib treatment for patients with locally advanced，
vances in targeted therapy and molecular markers[J]. Ann unresectable stage Ⅲc or metastatic melanoma and acti-
Surg Oncol，2015，22（11）：3451-3458. vating exon 15 BRAF mutations other than V600E[J].
[15] BURBIDGE T E，BASTIAN B C，GUO D，et al. Associa- Melanoma Res，2017，27（6）：585-590.
tion of indoor tanning exposure with age at melanoma diag- [26] RIBAS A，GONZALEZ R，PAVLICK A，et al. Combina-
nosis and BRAF V600E mutations[J]. J Natl Cancer Inst， tion of vemurafenib and cobimetinib in patients with ad-
2019，111（11）：1228-1231. vanced BRAF（V600）-mutated melanoma：a phase 1b
[16] SI L，KONG Y，XU X，et al. Prevalence of BRAF V600E study[J]. Lancet Oncol，2014，15（9）：954-965.
mutation in Chinese melanoma patients：large scale analy- [27] RIBAS A，DAUD A，PAVLICK A C，et al. Extended
sis of BRAF and NRAS mutations in a 432-case cohort[J]. 5-year follow-up results of a phase ib study（BRIM7）of
Eur J Cancer，2012，48（1）：94-100. vemurafenib and cobimetinib Ⅰn BRAF-mutant melano-
[17] FLAHERTY K T，PUZANOV I，KIM K B，et al. Inhibi- ma[J]. Clin Cancer Res，2020，26（1）：46-53.
tion of mutated，activated BRAF in metastatic melano- [28] LARKIN J，ASCIERTO P A，DRÉNO B，et al. Combined
ma[J]. N Engl J Med，2010，363（9）：809-819. vemurafenib and cobimetinib in BRAF-mutated melano-
[18] GRIPPO J F，ZHANG W，HEINZMANN D，et al. A ma[J]. N Engl J Med，2014，371（20）：1867-1876.
phase Ⅰ ，randomized，open-label study of the multiple- [29] ASCIERTO P A，MCARTHUR G A，DRÉNO B，et al. Co-
dose pharmacokinetics of vemurafenib in patients with bimetinib combined with vemurafenib in advanced BRAF
BRAF V600E mutation-positive metastatic melanoma[J]. （V600）-mutant melanoma（coBRIM）：updated efficacy
Cancer Chemother Pharmacol，2014，73（1）：103-111. results from a randomised，double-blind，phase 3 trial[J].
[19] SI L，ZHANG X S，XU Z，et al. Vemurafenib in Chinese Lancet Oncol，2016，17（9）：1248-1260.
patients with BRAF V600 mutation-positive unresectable [30] 岳育杨，李育婷，刘佩佩，等.黑色素瘤分子靶向治疗研究
or metastatic melanoma：an open-label，multicenter phase 进展[J].中国老年学杂志，2019，39（13）：3336-3340.
Ⅰ study[J]. BMC Cancer，2018，18（1）：520. [31] GUTZMER R，STROYAKOVSKIY D，GOGAS H，et al.
[20] CHAPMAN P B，HAUSCHILD A，ROBERT C，et al. Im- Atezolizumab，vemurafenib，and cobimetinib as first-line
proved survival with vemurafenib in melanoma with treatment for unresectable advanced BRAFV600 muta-
BRAF V600E mutation[J]. N Engl J Med，2011，364（26）： tion-positive melanoma（IMspire150）：primary analysis of
2507-2516. the randomised，double-blind，placebo-controlled，phase 3
[21] CHAPMAN P B，ROBERT C，LARKIN J，et al. Vemu- trial[J]. Lancet，2020，395（10240）：1835-1844.
rafenib in patients with BRAFV600 mutation-positive [32] FALCHOOK G S，LONG G V，KURZROCK R，et al.
metastatic melanoma：final overall survival results of the Dabrafenib in patients with melanoma，untreated brain me-
randomized BRIM-3 study[J]. Ann Oncol，2017，28（10）： tastases，and other solid tumours：a phase 1 dose-escala-
2581-2587. tion trial[J]. Lancet，2012，379（9829）：1893-1901.
[22] PUZANOV I，AMARAVADI R K，MCARTHUR G A，et [33] ASCIERTO P A，MINOR D，RIBAS A，et al. Phase Ⅱ
al. Long-term outcome in BRAF（V600E）melanoma pa- trial （BREAK-2） of the BRAF inhibitor dabrafenib
tients treated with vemurafenib：patterns of disease pro- （GSK2118436）in patients with metastatic melanoma[J]. J

中国药房 2021年第32卷第12期 China Pharmacy 2021 Vol. 32 No. 12 ·1535 ·